Swiss biotech firm NLS Pharmaceutics Ltd, which focuses on the development of novel treatments for the central nervous system (CNS)—in particular attention deficit hyperactivity disorder (ADHD) as well as hypersomnias (including narcolepsy, idiopathic hypersomnia, and Kleine Levin syndrome)—and other neurological diseases, has received a notice of allowance for a patent from the the Canadian Intellectual Property Office (CIPO) for a sleep disorder-related patent family.
Canadian Patent No. 2,825,275, entitled “Lauflumide and the enantiomers thereof, method for preparing same and therapeutic uses thereof” (inventor: NLS co-founder Eric Konofal), was allowed by the CIPO on May 30, 2019. The allowed invention claims concepts related to the use of lauflumide or the enantiomers thereof in the treatment of ADHD, narcolepsy, or idiopathic hypersomnia. Lauflumide is a wake-promoting compound structurally similar to modafinil. The Canadian patent to be issued expires in January 2032.
“We are extremely pleased with the continued development of our patent portfolio. The issuance of these patents is another major step in the development of a robust patent portfolio of NLS, including for the treatment of ADHD and narcolepsy, both fast growing neurological disorders with high unmet medical needs,” says Alex Zwyer, CEO of NLS, in a release.